Novel Molecular Imaging Agents to Detect Biomarkers of Metastatic Breast Cancer
Final rept. 15 Aug 2004-31 Dec 2005
CASE WESTERN RESERVE UNIV CLEVELAND OH
Pagination or Media Count:
We propose to develop novel molecular imaging agents to detect enzyme biomarkers of metastatic breast cancer. These imaging agents are detected using magnetic resonance imaging MRI only if they encounter enzymes that are present in metastatic breast tumors. Unlike standard MRI agents, these novel agents are detected by a unique mechanism that allows for evaluations of multiple enzymes during the same MRI experiment. The ability to simultaneously detect multiple enzyme biomarkers within a single MRI scan session will reduce scan times and patient discomfort. The unique detection mechanism employed by these MRI agents will take full advantage of new high-field clinical MRI scanners this is in contrast to standard MRI agents, which show only limited improvements at high magnetic fields. We will generate these novel agents using standard chemistry protocols. We ll optimize our MRI methods to detect enzyme biomarkers with these agents, and we will use well-established fluorescence imaging methods to validate our results. Finally, we ll apply these agents to detect the enzyme biomarkers within metatstatic breast tumor cells grown in mice. As a long-term goal, these novel molecular imaging agents will be further developed for clinical assessments of metastatic breast cancer.
- Medicine and Medical Research